India’s Emcure Pharmaceuticals has filed draft papers with the market regulator for an initial public offering, which a source with direct knowledge of the matter said could be worth up to 50 billion rupees ($671.89 million).
Emcure is the latest Indian company to tap capital markets this year in a fund-raising frenzy driven by abundant liquidity and record-high stock markets.
After food-delivery firm Zomato’s stellar market debut last month, Yum Brands’ largest Indian franchisee Devyani International saw strong demand for its initial share sale.
The source requested anonymity as he was not authorised to speak to media.
Source: Reuters
By Aditi Shah
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.